Clinical OMICS

JUL-AUG 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/853204

Contents of this Issue

Navigation

Page 35 of 47

34 Clinical OMICs July/August 2017 www.clinicalomics.com In the Lab A ll around the world, human sam- ples are stored in laboratories, hospitals, and specialized facilities. These collections vary significantly in size—from single labs housing speci- mens for individual projects, to large, university-based biobanks. In the United States alone, there are thou- sands of such facilities. "Anybody that's systemically collecting samples is considered a biobank," said Andrew Brooks, Ph.D., COO at RUCDR Infinite Biologics, a Rutgers University-based biorepository. "There are biobanks all over the place, and [there is] a huge, growing community." Despite the growth in bioreposito- ries, technical and operational hurdles still stand in the way of investigators procuring the right samples for their research. In a 2011 National Cancer Institute (NCI) survey of 727 cancer researchers, 47 percent reported hav- ing difficulty obtaining quality biospe- cimens. And as the field of precision medicine continues to accelerate, the demand for high-quality samples will likely continue to grow. "Many investigators are constantly looking for access to biosamples," said Stephen Thibodeau, Ph.D., a co-di- rector of the biorepositories program at the Mayo Clinic. "Because it's just really hard to get good samples that are well annotated and meet the spe- cific criteria that you want to have large enough numbers." Big repositories, such as those estab- lished by RUCDR Infinite Biologics and the Mayo Clinic, are trying to respond to these demands by provid- ing access to samples, as well as the facilities to process, store and manage them. Often, these facilities also pro- vide access to researchers outside of their respective institutions. "Right now, there are lots of large programs that exist academically and commercially that are doing prospec- tive collections, like us [at RUCDR]," Dr. Brooks said. "People are generat- ing biological assets for future use to help decrease or to make the hurdle a bit lower to get access to samples." Improving Annotation While many biorepostitories and com- mercial specimen-researcher match- makers are working to improve access to biospecimens, uniform and consis- tent clinical annotation remains a sig- nificant hurdle for researchers looking to gather multiple specimens from multiple sources for their work. "In order to get pathologists, radiol- ogists, oncologists and surgeons to produce data that can be used to anno- tate tissue, there need to be standards that are adopted across all fields and across the entire nation," Mary E. Edg- erton, a pathology professor at the MD Anderson Cancer Center in Houston, told Clinical OMICs. "While pathol- ogy leads in this area, only 5 to 10% of pathology laboratories are actually collecting the data in a discretized format." Though samples collected at uni- versity hospitals are usually anno- tated, this is not always the case in smaller community hospitals—and even at the large centers, this process is not yet completely standardized. "Until we're all hooked up in elec- tronic health records, that are com- patible to each other and that people can query, I think it will continue to be challenging," said Kay Washington, M.D., Ph.D., director of the Western division of the Cooperative Human Tissue Network (CHTN), an organiza- tion established by the NCI to meet the increasing demands for human tissue. "I think we need better electronic tools all around." This is one of the focuses of the CHTN. "We do simple things like download the schedule for the oper- ating rooms onto our system to flag potential patient cases," Dr. Wash- ington says. "Some of the sites are developing tools to allow investiga- tors outside their institutions to look at what they have in the bank at the moment and pick specimens that might suit their needs." Short Supply Some areas of research face a bigger supply shortage than others. Though paraffin blocks are widely available, they cannot be applied across all Barriers in Bio banking Although the Demand for Human Samples is Rising, Obstacles Remain in Connecting Researchers with the Right Specimens By Diana Kwon, Contributing Editor

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JUL-AUG 2017